242 related articles for article (PubMed ID: 36750136)
1. The potential of CD38 protein as a target for autoimmune diseases.
Ye X; Zhao Y; Ma W; Ares I; Martínez M; Lopez-Torres B; Martínez-Larrañaga MR; Wang X; Anadón A; Martínez MA
Autoimmun Rev; 2023 Apr; 22(4):103289. PubMed ID: 36750136
[TBL] [Abstract][Full Text] [Related]
2. The NADase enzyme CD38: an emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis.
Peclat TR; Shi B; Varga J; Chini EN
Curr Opin Rheumatol; 2020 Nov; 32(6):488-496. PubMed ID: 32941246
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.
Cole S; Walsh A; Yin X; Wechalekar MD; Smith MD; Proudman SM; Veale DJ; Fearon U; Pitzalis C; Humby F; Bombardieri M; Axel A; Adams H; Chiu C; Sharp M; Alvarez J; Anderson I; Madakamutil L; Nagpal S; Guo Y
Arthritis Res Ther; 2018 May; 20(1):85. PubMed ID: 29720240
[TBL] [Abstract][Full Text] [Related]
4. Macrophage: Key player in the pathogenesis of autoimmune diseases.
Yang S; Zhao M; Jia S
Front Immunol; 2023; 14():1080310. PubMed ID: 36865559
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes.
Frazzei G; van Vollenhoven RF; de Jong BA; Siegelaar SE; van Schaardenburg D
Front Immunol; 2022; 13():899372. PubMed ID: 35844538
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin in autoimmune disorders: current knowledge and future perspective.
Xu C; Wu Y; Liu N
Inflammopharmacology; 2022 Apr; 30(2):385-396. PubMed ID: 35235108
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-13: A promising therapeutic target for autoimmune disease.
Mao YM; Zhao CN; Leng J; Leng RX; Ye DQ; Zheng SG; Pan HF
Cytokine Growth Factor Rev; 2019 Feb; 45():9-23. PubMed ID: 30581068
[TBL] [Abstract][Full Text] [Related]
8. Pentraxin 3: A promising therapeutic target for autoimmune diseases.
Wu Q; Cao F; Tao J; Li X; Zheng SG; Pan HF
Autoimmun Rev; 2020 Dec; 19(12):102584. PubMed ID: 32534154
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Potential of Galectin-1 and Galectin-3 in Autoimmune Diseases.
He YS; Hu YQ; Xiang K; Chen Y; Feng YT; Yin KJ; Huang JX; Wang J; Wu ZD; Wang GH; Pan HF
Curr Pharm Des; 2022; 28(1):36-45. PubMed ID: 34579628
[TBL] [Abstract][Full Text] [Related]
10. The pathogenic, therapeutic and diagnostic role of exosomal microRNA in the autoimmune diseases.
Mirzaei R; Zamani F; Hajibaba M; Rasouli-Saravani A; Noroozbeygi M; Gorgani M; Hosseini-Fard SR; Jalalifar S; Ajdarkosh H; Abedi SH; Keyvani H; Karampoor S
J Neuroimmunol; 2021 Sep; 358():577640. PubMed ID: 34224949
[TBL] [Abstract][Full Text] [Related]
11. Metabolic alterations of the immune system in the pathogenesis of autoimmune diseases.
Blanco LP; Kaplan MJ
PLoS Biol; 2023 Apr; 21(4):e3002084. PubMed ID: 37098006
[TBL] [Abstract][Full Text] [Related]
12. Natural products action on pathogenic cues in autoimmunity: Efficacy in systemic lupus erythematosus and rheumatoid arthritis as compared to classical treatments.
Cao F; Cheng MH; Hu LQ; Shen HH; Tao JH; Li XM; Pan HF; Gao J
Pharmacol Res; 2020 Oct; 160():105054. PubMed ID: 32645358
[TBL] [Abstract][Full Text] [Related]
13. Programmed cell death in autoimmune diseases: ferroptosis.
Sun J; Huang L; Wang J; Hu Y; Wang W; Zhu H
Ann Biol Clin (Paris); 2024 Apr; 82(1):33-42. PubMed ID: 38638017
[TBL] [Abstract][Full Text] [Related]
14. Dickkopf-1 as a promising therapeutic target for autoimmune diseases.
Tao SS; Cao F; Sam NB; Li HM; Feng YT; Ni J; Wang P; Li XM; Pan HF
Clin Immunol; 2022 Dec; 245():109156. PubMed ID: 36257529
[TBL] [Abstract][Full Text] [Related]
15. Identification of common susceptibility genes and drug target genes in multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis and its value to guide clinical treatment.
Liu Y; Rang X; Zou X; Wang X; Zhang X; Wang Y; Xu C; Fu J
Mult Scler Relat Disord; 2022 Feb; 58():103504. PubMed ID: 35030369
[TBL] [Abstract][Full Text] [Related]
16. Multipotent Mesenchymal Stromal Cells in Rheumatoid Arthritis and Systemic Lupus Erythematosus; From a Leading Role in Pathogenesis to Potential Therapeutic Saviors?
El-Jawhari JJ; El-Sherbiny Y; McGonagle D; Jones E
Front Immunol; 2021; 12():643170. PubMed ID: 33732263
[TBL] [Abstract][Full Text] [Related]
17. NLRP3: A promising therapeutic target for autoimmune diseases.
Shen HH; Yang YX; Meng X; Luo XY; Li XM; Shuai ZW; Ye DQ; Pan HF
Autoimmun Rev; 2018 Jul; 17(7):694-702. PubMed ID: 29729449
[TBL] [Abstract][Full Text] [Related]
18. IL-33 in autoimmunity; possible therapeutic target.
Yuan C
Int Immunopharmacol; 2022 Jul; 108():108887. PubMed ID: 35729828
[TBL] [Abstract][Full Text] [Related]
19. Mitochondria in innate immunity signaling and its therapeutic implications in autoimmune diseases.
Jiao Y; Yan Z; Yang A
Front Immunol; 2023; 14():1160035. PubMed ID: 37122709
[TBL] [Abstract][Full Text] [Related]
20. Understanding the immunopathogenesis of autoimmune diseases by animal studies using gene modulation: A comprehensive review.
Lee KH; Ahn BS; Cha D; Jang WW; Choi E; Park S; Park JH; Oh J; Jung DE; Park H; Park JH; Suh Y; Jin D; Lee S; Jang YH; Yoon T; Park MK; Seong Y; Pyo J; Yang S; Kwon Y; Jung H; Lim CK; Hong JB; Park Y; Choi E; Shin JI; Kronbichler A
Autoimmun Rev; 2020 Mar; 19(3):102469. PubMed ID: 31918027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
